Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

Launched by UNIVERSITY OF COLOGNE · Apr 8, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with classical Hodgkin lymphoma (cHL) who have either relapsed after initial treatment or did not respond to their first treatment. The trial combines a medication called pembrolizumab, which helps the immune system fight cancer, with standard chemotherapy regimens known as ICE and DHAP. The goal is to find a treatment that is both effective and has fewer side effects than traditional high-dose chemotherapy, which can be very harsh on the body.

To participate in this trial, individuals should have a confirmed diagnosis of first relapse or primary refractory classical Hodgkin lymphoma. Unfortunately, those with a different type of Hodgkin lymphoma or certain other conditions won't be eligible. While participating, patients can expect close monitoring and care from the medical team as they receive this new combination therapy. The trial is currently recruiting participants, and it welcomes people of all genders aged between 18 and 74.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed first relapse of cHL or primary refractory cHL
• Exclusion Criteria:
• • Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma